EMSY and CCND1 amplification in familial breast cancer: From the Ontario site of the Breast Cancer Family Registry

Breast Cancer Research and Treatment

Volumn 127, Issue 3, 2011, Pages 831-839

  Bane, Anita L ^a,b   Mulligan, Anna Marie ^c,d   Pinnaduwage, Dushanthi ^e   O'Malley, Frances P ^c,d   Andrulis, Irene L ^d,e  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

CCND1 amplification; EMSY amplification; Familial breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER MORPHOLOGY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CONTROLLED STUDY; FAMILIAL CANCER; GENE AMPLIFICATION; GENE DELETION; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENE; ONCOGENE CCND1; ONCOGENE EMSY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CANADA; CYCLIN D1; FEMALE; GENE AMPLIFICATION; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958290282     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1380-y     Document Type: Article

References (50)

1. SD Merajver TS Frank J Xu, et al. 1995 Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer Clin Cancer Res 1 539 544 9816013 1:CAS:528:DyaK2sXht1CqtLY%3D
2. NC Turner JS Reis-Filho AM Russell, et al. 2007 BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 26 2126 2132 17016441 10.1038/sj.onc.1210014 1:CAS:528:DC%2BD2sXjsFSiu7c%3D (Pubitemid 46514749)
3. N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 814 819 15510162 10.1038/nrc1457 1:CAS:528: DC%2BD2cXos1ymu7g%3D (Pubitemid 39331153)
4. T Sorlie R Tibshirani J Parker, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 12829800 10.1073/pnas.0932692100 1:CAS:528: DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
5. AL Bane D Pinnaduwage S Colby, et al. 2009 Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors Breast Cancer Res Treat 117 183 191 18563556 10.1007/s10549-008-0087-1 1:CAS:528:DC%2BD1MXpvFyiur0%3D
6. SR Lakhani JS Reis-Filho L Fulford, et al. 2005 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 5175 5180 16033833 10.1158/1078-0432.CCR-04-2424 1:CAS:528:DC%2BD2MXmt12qtbk%3D (Pubitemid 41003703)
7. JM Lancaster R Wooster J Mangion, et al. 1996 BRCA2 mutations in primary breast and ovarian cancers Nat Genet 13 238 240 8640235 10.1038/ng0696-238 1:CAS:528:DyaK28XktlOhu74%3D (Pubitemid 26000445)
8. N Collins R Wooster MR Stratton 1997 Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers Br J Cancer 76 1150 1156 9365162 10.1038/bjc.1997.526 1:CAS:528:DyaK2sXntlOntr0%3D (Pubitemid 27448010)
9. L Hughes-Davies D Huntsman M Ruas, et al. 2003 EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer Cell 115 523 535 14651845 10.1016/S0092-8674(03)00930-9 1:CAS:528:DC%2BD3sXps1Oht7c%3D (Pubitemid 37506042)
10. WA van Hattem R Carvalho A Li, et al. 2008 Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas Int J Clin Exp Pathol 1 343 351 18787609
11. LA Brown J Irving R Parker, et al. 2006 Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas Gynecol Oncol 100 264 270 16236351 10.1016/j.ygyno.2005.08.026 1:CAS:528: DC%2BD28XjsFKrsQ%3D%3D (Pubitemid 43075259)
12. M Schwab 1998 Amplification of oncogenes in human cancer cells Bioessays 20 473 479 9699459 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.0. CO;2-N 1:STN:280:DyaK1czmsVKitw%3D%3D (Pubitemid 28320609)
13. G Peters V Fantl R Smith, et al. 1995 Chromosome 11q13 markers and D-type cyclins in breast cancer Breast Cancer Res Treat 33 125 135 7749140 10.1007/BF00682720 1:CAS:528:DyaK2MXksFagtbk%3D
14. J Karlseder R Zeillinger C Schneeberger, et al. 1994 Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer Genes Chromosomes Cancer 9 42 48 7507699 10.1002/gcc.2870090108 1:CAS:528: DyaK2cXmtVWqtbg%3D (Pubitemid 24007495)
15. JS Reis-Filho K Savage MB Lambros, et al. 2006 Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis Mod Pathol 19 7 999 1009 16648863 10.1038/modpathol.3800621 1:CAS:528:DC%2BD28Xls1KitLY%3D
16. SA Vaziri RR Tubbs G Darlington, et al. 2001 Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers Mol Pathol 54 259 263 11477142 10.1136/mp.54.4.259 1:CAS:528:DC%2BD38XnvFSjtL8%3D (Pubitemid 32730403)
17. EM John JL Hopper JC Beck, et al. 2004 The breast cancer family registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer Breast Cancer Res 6 R375 R389 15217505 10.1186/bcr801
18. Tavassoli T, Devilee P (2003) Pathology & genetics. Tumours of the breast and female genital organs. IARC Press, Lyon
19. O'Malley FP, Pinder SE (2006) Breast pathology: a volume in the foundations in diagnostic pathology. Churchill Livingstone, New York
20. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
21. J Kononen L Bubendorf A Kallioniemi, et al. 1998 Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 844 847 9662379 10.1038/nm0798-844 1:CAS:528:DyaK1cXktlKntr8%3D (Pubitemid 28331029)
22. AL Bane JC Beck I Bleiweiss, et al. 2007 BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays Am J Surg Pathol 31 121 128 17197928 10.1097/01.pas.0000213351.49767.0f (Pubitemid 46036911)
23. IL Andrulis H Anton-Culver J Beck, et al. 2002 Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations Hum Mutat 20 65 73 12112659 10.1002/humu.10097 1:CAS:528:DC%2BD38XlslKrtrc%3D (Pubitemid 34747718)
24. R Youil BW Kemper RG Cotton 1995 Screening for mutations by enzyme mismatch cleavage with T4 endonuclease VII Proc Natl Acad Sci USA 92 87 91 7816853 10.1073/pnas.92.1.87 1:CAS:528:DyaK2MXjtVegtbo%3D
25. R Espinosa 3rd MM Le Beau 1997 Gene mapping by FISH Methods Mol Biol 68 53 76 9055250 1:CAS:528:DyaK28XntlGktr0%3D
26. DC Allred JM Harvey M Berardo, et al. 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 155 168 9504686 1:STN:280:DyaK1c7mtlaitg%3D%3D (Pubitemid 28144151)
27. JM Harvey GM Clark CK Osborne, et al. 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
28. AC Wolff ME Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18 43 19548375 1:CAS:528:DC%2BD2sXhsVOmu74%3D (Pubitemid 46174133)
29. AM Mulligan D Pinnaduwage SB Bull, et al. 2008 Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort Clin Cancer Res 14 4168 4174 18593996 10.1158/1078-0432.CCR-07-4543 1:CAS:528:DC%2BD1cXnvFyksr4%3D
30. CL Liu W Prapong Y Natkunam, et al. 2002 Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays Am J Pathol 161 1557 1565 12414504 10.1016/S0002-9440(10)64434-3 1:CAS:528:DC%2BD38XptV2gtrk%3D (Pubitemid 35265516)
31. CL Liu KD Montgomery Y Natkunam, et al. 2005 TMA-combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays Mod Pathol 18 1641 1648 16258508 1:CAS:528:DC%2BD2MXht1aqsr7J (Pubitemid 41670665)
32. LA Brown K Johnson S Leung, et al. 2009 Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers Breast Cancer Res Treat 121 2 347 354 19636701 10.1007/s10549-009-0479-x
33. T Kirkegaard KV Nielsen LB Jensen, et al. 2008 Genetic alterations of CCND1 and EMSY in breast cancers Histopathology 52 698 705 18393977 10.1111/j.1365-2559.2008.03007.x 1:STN:280:DC%2BD1c3ns12jsQ%3D%3D (Pubitemid 351600044)
34. C Rodriguez L Hughes-Davies H Valles, et al. 2004 Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome Clin Cancer Res 10 5785 5791 15355907 10.1158/1078-0432.CCR-03-0410 1:CAS:528:DC%2BD2cXntlyjs7s%3D (Pubitemid 39180956)
35. DM Barnes 1997 Cyclin D1 in mammary carcinoma J Pathol 181 267 269 9155710 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X 1:STN:280:DyaK2szgtVKqsg%3D%3D (Pubitemid 27156837)
36. AJ Butt CM McNeil EA Musgrove, et al. 2005 Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E Endocr Relat Cancer 12 Suppl 1 S47 S59 16113099 10.1677/erc.1.00993 1:CAS:528:DC%2BD2MXhtFyitbzO (Pubitemid 41395413)
37. A Arnold A Papanikolaou 2005 Cyclin D1 in breast cancer pathogenesis J Clin Oncol 23 4215 4224 15961768 10.1200/JCO.2005.05.064 1:CAS:528: DC%2BD2MXmt1els7c%3D (Pubitemid 46211327)
38. E Neuman MH Ladha N Lin, et al. 1997 Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 Mol Cell Biol 17 5338 5347 9271411 1:CAS:528:DyaK2sXlslartL0%3D (Pubitemid 27357632)
39. RM Zwijsen RS Buckle EM Hijmans, et al. 1998 Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1 Genes Dev 12 3488 3498 9832502 10.1101/gad.12.22.3488 1:CAS:528: DyaK1cXnvVOhu7c%3D (Pubitemid 28553241)
40. RM Zwijsen E Wientjens R Klompmaker, et al. 1997 CDK-independent activation of estrogen receptor by cyclin D1 Cell 88 405 415 9039267 10.1016/S0092-8674(00)81879-6 1:CAS:528:DyaK2sXhtFagtbw%3D (Pubitemid 27131382)
41. F Courjal M Cuny J Simony-Lafontaine, et al. 1997 Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups Cancer Res 57 4360 4367 9331099 1:CAS:528: DyaK2sXmsFCgsrs%3D (Pubitemid 27413447)
42. LR Zukerberg WI Yang M Gadd, et al. 1995 Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene Mod Pathol 8 560 567 7675778 1:STN:280:DyaK2Mvgs1ajtw%3D%3D
43. M Barbareschi P Pelosio O Caffo, et al. 1997 Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression Int J Cancer 74 171 174 9133450 10.1002/(SICI)1097-0215(19970422)74:2<171::AID-IJC5>3.0.CO;2-W 1:CAS:528:DyaK2sXjtleqsLo%3D (Pubitemid 27234505)
44. K Jirstrom M Stendahl L Ryden, et al. 2005 Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification Cancer Res 65 8009 8016 16140974 (Pubitemid 41297281)
45. M Stendahl A Kronblad L Ryden, et al. 2004 Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients Br J Cancer 90 1942 1948 15138475 10.1038/sj.bjc.6601831 1:CAS:528:DC%2BD2cXjvVals7w%3D (Pubitemid 38746334)
46. I Bieche M Olivi C Nogues, et al. 2002 Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays Br J Cancer 86 580 586 11870541 10.1038/sj.bjc.6600109 1:CAS:528:DC%2BD38XislCmt78%3D (Pubitemid 34185096)
47. R Seshadri CS Lee R Hui, et al. 1996 Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis Clin Cancer Res 2 1177 1184 9816285 1:STN:280:DyaK1M%2FjsFWgsQ%3D%3D (Pubitemid 26238449)
48. K Al-Kuraya P Schraml J Torhorst, et al. 2004 Prognostic relevance of gene amplifications and coamplifications in breast cancer Cancer Res 64 8534 8540 15574759 10.1158/0008-5472.CAN-04-1945 1:CAS:528:DC%2BD2cXhtVCjs7zJ (Pubitemid 39552065)
49. J Bostner M Ahnstrom Waltersson T Fornander, et al. 2007 Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer Oncogene 26 6997 7005 17486065 10.1038/sj.onc. 1210506 1:CAS:528:DC%2BD2sXht1Wgt7rJ (Pubitemid 350014611)
50. E Schuuring E Verhoeven H van Tinteren, et al. 1992 Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer Cancer Res 52 5229 5234 1394126 1:CAS:528:DyaK38XmtlWhtbY%3D